Immunotherapy: Reshape the Tumor Immune Microenvironment

被引：219
作者：
Lv, Bingzhe [1 ,2 ]
Wang, Yunpeng [1 ,2 ]
Ma, Dongjiang [1 ,2 ]
Cheng, Wei [1 ,2 ]
Liu, Jie [1 ,2 ]
Yong, Tao [1 ,2 ]
Chen, Hao [3 ,4 ]
Wang, Chen [1 ,3 ]
机构：
[1] Lanzhou Univ, Dept Gen Surg, Hosp 2, Lanzhou, Peoples R China
[2] Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China
[3] Lanzhou Univ, Key Lab Digest Syst Tumors Gansu Prov, Hosp 2, Lanzhou, Peoples R China
[4] Lanzhou Univ, Dept Surg Oncol, Hosp 2, Lanzhou, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词：
tumor immune microenvironment; immunotherapy; immune cell; antibody; small molecule inhibitor; REGULATORY T-CELLS; CHIMERIC ANTIGEN RECEPTOR; FOCAL ADHESION KINASE; SUPPRESSOR-CELLS; SIPULEUCEL-T; CHECKPOINT BLOCKADE; ANTITUMOR IMMUNITY; ADVANCED MELANOMA; PD-1; EXPRESSION; DENDRITIC CELLS;
D O I：
10.3389/fimmu.2022.844142
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc. The interactions between these components, which are divided into anti-tumor and pro-tumor, determine the trend of anti-tumor immunity. Although the immune system can eliminate tumor through the cancer-immune cycle, tumors appear to eventually evade from immune surveillance by shaping an immunosuppressive microenvironment. Immunotherapy reshapes the TIME and restores the tumor killing ability of anti-tumor immune cells. Herein, we review the function of immune cells within the TIME and discuss the contribution of current mainstream immunotherapeutic approaches to remolding the TIME. Changes in the immune microenvironment in different forms under the intervention of immunotherapy can shed light on better combination treatment strategies.
引用
收藏
页数：15
相关论文
共 226 条
  • [1] Tim-3 finds its place in the cancer immunotherapy landscape
    Acharya, Nandini
    Sabatos-Peyton, Catherine
    Anderson, Ana Carrizosa
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [2] IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
    Adachi, Keishi
    Kano, Yosuke
    Nagai, Tomohiko
    Okuyama, Namiko
    Sakoda, Yukimi
    Tamada, Koji
    [J]. NATURE BIOTECHNOLOGY, 2018, 36 (04) : 346 - +
  • [3] A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
    Adusumilli, Prasad S.
    Zauderer, Marjorie G.
    Riviere, Isabelle
    Solomon, Stephen B.
    Rusch, Valerie W.
    O'Cearbhaill, Roisin E.
    Zhu, Amy
    Cheema, Waseem
    Chintala, Navin K.
    Halton, Elizabeth
    Pineda, John
    Perez-Johnston, Rocio
    Tan, Kay See
    Daly, Bobby
    Araujo Filho, Jose A.
    Ngai, Daniel
    McGee, Erin
    Vincent, Alain
    Diamonte, Claudia
    Sauter, Jennifer L.
    Modi, Shanu
    Sikder, Devanjan
    Senechal, Brigitte
    Wang, Xiuyan
    Travis, William D.
    Gonen, Mithat
    Rudin, Charles M.
    Brentjens, Renier J.
    Jones, David R.
    Sadelain, Michel
    [J]. CANCER DISCOVERY, 2021, 11 (11) : 2748 - 2763
  • [4] Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
    Albini, Adriana
    Bruno, Antonino
    Noonan, Douglas M.
    Mortara, Lorenzo
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [5] Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
    Ali, Omar A.
    Lewin, Sarah A.
    Dranoff, Glenn
    Mooney, David J.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2016, 4 (02) : 95 - 100
  • [6] Macrophage-Based Approaches for Cancer Immunotherapy
    Anderson, Nicholas R.
    Minutolo, Nicholas G.
    Gill, Saar
    Klichinsky, Michael
    [J]. CANCER RESEARCH, 2021, 81 (05) : 1201 - 1208
  • [7] Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
    Antonios, Joseph P.
    Soto, Horacio
    Everson, Richard G.
    Moughon, Diana
    Orpilla, Joey R.
    Shin, Namjo P.
    Sedighim, Shaina
    Treger, Janet
    Odesa, Sylvia
    Tucker, Alexander
    Yong, William H.
    Li, Gang
    Cloughesy, Timothy F.
    Liau, Linda M.
    Prins, Robert M.
    [J]. NEURO-ONCOLOGY, 2017, 19 (06) : 796 - 807
  • [8] Ascierto PA, 2017, ANN ONCOL, V28, pv611, DOI [10.1093/annonc/mdx440.011, DOI 10.1093/ANNONC/MDX440.011]
  • [9] Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
    Atkinson, Victoria
    Khattak, Adnan
    Haydon, Andrew
    Eastgate, Melissa
    Roy, Amitesh
    Prithviraj, Prashanth
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [10] Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
    Bastid, Jeremy
    Regairaz, Anne
    Bonnefoy, Nathalie
    Dejou, Cecile
    Giustiniani, Jerome
    Laheurte, Caroline
    Cochaud, Stephanie
    Laprevotte, Emilie
    Funck-Brentano, Elisa
    Hemon, Patrice
    Gros, Laurent
    Bec, Nicole
    Larroque, Christian
    Alberici, Gilles
    Bensussan, Armand
    Eliaou, Jean-Francois
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (03) : 254 - 265
12345678910